Pfizergan Offers Warm Embrace For Pfizer’s Internal And Allergan’s External R&D
Pfizer R&D chief Mikael Dolsten and his counterpart at Allergan, David Nicholson, oversee very different research organizations, but in interviews at the J.P. Morgan Healthcare Conference the two heads of R&D insisted the chasm between their research models is not so vast.
You may also be interested in...
Boehringer expects Jardiance’s new chronic kidney disease indication to keep its sales growing by double-digit percentages over the coming years, aided by the drug’s ability to reduce hospitalizations.
As Medicare drug price negotiations creep closer to reality, industry leaders are turning attention to the challenges of implementation and commercial concerns.
The company presented its pipeline to investors during an R&D day, outlining expansion plans for Voxzogo and Roctavian as well as several early pipeline drugs.